• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

Jan. 21, 2011

View Archived Issues

MicroRNA 34a Takes Stem Cell Powers from Prostate Tumors

A study brought new insights into miR-34a's role in prostate cancer this week. The microRNA appears to be important for preventing prostate cancer cells from developing cancer stem cell-like properties. Systemic delivery of a miR-34a mimic inhibited tumor growth and metastasis in mice with xenografted prostate tumors. Read More

MannKind Shares Sink on 2nd Afrezza Complete Response

MannKind Corp. took one squarely on the chin Thursday as the market responded to breaking news late Wednesday that the FDA had issued a second complete response letter for inhaled insulin candidate Afrezza (insulin human [rDNA origin] to treat adults with Type I and Type II diabetes. (See BioWorld Today, Jan. 20, 2011.) Read More

Other News To Note

NeoStem Inc., of New York, acquired Progenitor Cell Therapy LLC, of Allendale, N.J. Terms of the transaction were not disclosed, but NeoStem recently raised $19 million to fund the acquisition. The deal is designed to offer single source for the collection, storage, manufacturing, therapeutic development and transportation of cells for cell-based medicine and regenerative science. Investment banking firm LifeTech Capital, a division of Aurora Capital LLC, advised NeoStem by providing a valuation analysis of the transaction. (See BioWorld Today, Nov. 17, 2010.) Read More

Stock Movers

Read More

Clinic Roundup

Allos Therapeutics Inc., of Westminster, Colo., said data from the Phase II PROPEL study published in the Journal of Clinical Oncology showed that Folotyn (pralatrexate) in relapsed or refractory peripheral T-cell lymphoma patients produced an overall response rate of 29 percent, with 11 percent of patients experiencing a complete response or unconfirmed complete response. Folotyn was granted accelerated approval in PTCL in 2009. Read More

Ardea Follows Positive Gout Results with $71.5M Offering

January already had been a pretty good month for Ardea Biosciences Inc. and it got even better on Thursday. Read More

Public Offering to Net a Cool $40M for ArQule

ArQule Inc. priced a public offering of 7 million shares of common stock at $6.15 per share to boost research and development of its pipeline of cancer products. The offering, which is expected to close Jan. 25, grants underwriters a 30-day option to purchase up to 1.05 million additional shares to cover overallotments. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 6, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 6, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 3, 2025
  • Gilead Sciences divulges new compounds to treat herpes virus infection

    BioWorld Science
    Gilead Sciences Inc. has synthesized indoline compounds acting as DNA helicase-primase complex (human herpes simplex virus) and viral replication inhibitors...
  • Biotech deal illustration

    City hits the town with $1B-plus deal with Biogen

    BioWorld
    A development deal with Biogen Inc. could eventually bring City Therapeutics Inc. about $1 billion in milestone payments. It’s a step in the direction the company...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe